Chugai Pharmaceutical Co (STU:CUP) E10: €0.93 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CUP Chugai Pharmaceutical Co Ltd STU:CUP
95 GF Score
Price €36.79
GF Value €42.02
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co E10?

Chugai Pharmaceutical Co STU:CUP -5.35% 95 E10 is €0.93 as of Jun. 2026. GuruFocus rates STU:CUP with a GF Score™ of 95/100 and a GF Value™ of €42.02 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.382. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.93 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Chugai Pharmaceutical Co's average E10 Growth Rate was 18.60% per year. During the past 3 years, the average E10 Growth Rate was 20.60% per year. During the past 5 years, the average E10 Growth Rate was 25.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Chugai Pharmaceutical Co was 29.80% per year. The lowest was 16.20% per year. And the median was 24.95% per year.

As of today (2026-08-01), Chugai Pharmaceutical Co's current stock price is €36.79. Chugai Pharmaceutical Co's E10 for the quarter that ended in Jun. 2026 was €0.93. Chugai Pharmaceutical Co's Shiller PE Ratio of today is 39.56.

During the past 13 years, the highest Shiller PE Ratio of Chugai Pharmaceutical Co was 132.28. The lowest was 34.06. And the median was 55.80.


Chugai Pharmaceutical Co  (STU:CUP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chugai Pharmaceutical Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=36.79/0.93
=39.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Chugai Pharmaceutical Co was 132.28. The lowest was 34.06. And the median was 55.80.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Chugai Pharmaceutical Co E10 Related Terms


Chugai Pharmaceutical Co E10 Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co E10 Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.63 0.69 0.80 0.86

Chugai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.86 0.86 0.92 0.93

STU:CUP vs LLY, JNJ, ABBV: E10 Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Shiller PE Ratio falls into.


STU:CUP
95GF Score
Chugai Pharmaceutical Co Ltd STU:CUP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.382/113.6000*113.6000
=0.382

Current CPI (Jun. 2026) = 113.6000.

Chugai Pharmaceutical Co Quarterly Data

per share eps CPI Adj_EPS
201609 0.062 98.000 0.072
201612 0.052 98.400 0.060
201703 0.093 98.100 0.108
201706 0.086 98.500 0.099
201709 0.097 98.800 0.112
201712 0.071 99.400 0.081
201803 0.130 99.200 0.149
201806 0.098 99.200 0.112
201809 0.101 99.900 0.115
201812 0.106 99.700 0.121
201903 0.170 99.700 0.194
201906 0.170 99.800 0.194
201909 0.247 100.100 0.280
201912 0.201 100.500 0.227
202003 0.263 100.300 0.298
202006 0.255 99.900 0.290
202009 0.294 99.900 0.334
202012 0.252 99.300 0.288
202103 0.223 99.900 0.254
202106 0.324 99.500 0.370
202109 0.403 100.100 0.457
202112 0.467 100.100 0.530
202203 0.613 101.100 0.689
202206 0.311 101.800 0.347
202209 0.290 103.100 0.320
202212 0.436 104.100 0.476
202303 0.312 104.400 0.339
202306 0.330 105.200 0.356
202309 0.299 106.200 0.320
202312 0.353 106.800 0.375
202403 0.278 107.200 0.295
202406 0.400 108.200 0.420
202409 0.419 108.900 0.437
202412 0.345 110.700 0.354
202503 0.367 111.100 0.375
202506 0.354 111.700 0.360
202509 0.389 112.000 0.395
202512 0.427 113.000 0.429
202603 0.382 112.700 0.385
202606 0.382 113.600 0.382

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.93 mean?
Chugai Pharmaceutical Co (STU:CUP) has a E10 of €0.93 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's E10 too high?
Chugai Pharmaceutical Co's current E10 is €0.93. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's E10 compare to LLY and JNJ?
Chugai Pharmaceutical Co's E10 of €0.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current E10 is €0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (STU:CUP) is currently considered Modestly Undervalued. The stock's GF Value™ is €42.02, compared to a current price of €36.79 — trading 12.4% below its estimated fair value. The current E10 is €0.93. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Chugai Pharmaceutical Co (STU:CUP), the current E10 is €0.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (STU:CUP) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of €36.79 is trading 12.4% below its estimated GF Value™ of €42.02. GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for STU:CUP:

  • E10: €0.93
  • GF Value™: €42.02 vs. price of €36.79 (12.4% below fair value)
  • GF Score™: 95/100 with 1 warning sign

No single metric tells the full story. See the STU:CUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score

Get the complete analysis for STU:CUP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€36.79
Price
€42.02
GF Value